ATE458494T1 - Von der telomerase abgeleitete antigene peptide - Google Patents

Von der telomerase abgeleitete antigene peptide

Info

Publication number
ATE458494T1
ATE458494T1 AT03075681T AT03075681T ATE458494T1 AT E458494 T1 ATE458494 T1 AT E458494T1 AT 03075681 T AT03075681 T AT 03075681T AT 03075681 T AT03075681 T AT 03075681T AT E458494 T1 ATE458494 T1 AT E458494T1
Authority
AT
Austria
Prior art keywords
telomerase
antigen peptides
derived antigen
derived
peptides
Prior art date
Application number
AT03075681T
Other languages
English (en)
Inventor
Mona Moller
Jon Armund Eriksen
Gustav Gaudernack
Marianne Klemp Gjertsen
Ingvil Saeterdal
Stein Saebo-Larsen
Original Assignee
Gemvax As
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=19902234&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=ATE458494(T1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Gemvax As filed Critical Gemvax As
Application granted granted Critical
Publication of ATE458494T1 publication Critical patent/ATE458494T1/de

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/43—Enzymes; Proenzymes; Derivatives thereof
    • A61K38/45—Transferases (2)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/0005—Vertebrate antigens
    • A61K39/0011—Cancer antigens
    • A61K39/001154—Enzymes
    • A61K39/001157—Telomerase or TERT [telomerase reverse transcriptase]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/10—Transferases (2.)
    • C12N9/12—Transferases (2.) transferring phosphorus containing groups, e.g. kinases (2.7)
    • C12N9/1241—Nucleotidyltransferases (2.7.7)

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Engineering & Computer Science (AREA)
  • Organic Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Immunology (AREA)
  • Epidemiology (AREA)
  • Genetics & Genomics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Zoology (AREA)
  • Microbiology (AREA)
  • Wood Science & Technology (AREA)
  • Oncology (AREA)
  • General Engineering & Computer Science (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biomedical Technology (AREA)
  • Biotechnology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Mycology (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Hematology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
  • Enzymes And Modification Thereof (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
AT03075681T 1998-07-08 1999-06-30 Von der telomerase abgeleitete antigene peptide ATE458494T1 (de)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
NO19983141A NO313834B1 (no) 1998-07-08 1998-07-08 Telomeraseprotein eller -peptider, nukleinsyresekvenser som koder for disse, farmasöytiske sammensetninger inneholdende disseog fremgangsmÕter for Õ fremstille slike farmasöytiskesammensetninger til profylakse mot og behandling av kreft, samt

Publications (1)

Publication Number Publication Date
ATE458494T1 true ATE458494T1 (de) 2010-03-15

Family

ID=19902234

Family Applications (2)

Application Number Title Priority Date Filing Date
AT03075681T ATE458494T1 (de) 1998-07-08 1999-06-30 Von der telomerase abgeleitete antigene peptide
AT99928238T ATE247484T1 (de) 1998-07-08 1999-06-30 Von der telomerase abgeleitete antigene peptide

Family Applications After (1)

Application Number Title Priority Date Filing Date
AT99928238T ATE247484T1 (de) 1998-07-08 1999-06-30 Von der telomerase abgeleitete antigene peptide

Country Status (20)

Country Link
US (2) US7030211B1 (de)
EP (4) EP1362597B2 (de)
JP (2) JP4618657B2 (de)
CN (1) CN100376290C (de)
AR (2) AR020601A1 (de)
AT (2) ATE458494T1 (de)
AU (1) AU756094B2 (de)
CA (2) CA2336743C (de)
CY (1) CY1109978T1 (de)
CZ (1) CZ303215B6 (de)
DE (2) DE69942072D1 (de)
DK (2) DK1362597T3 (de)
ES (2) ES2200526T5 (de)
HK (1) HK1039068B (de)
HU (1) HU230007B1 (de)
NO (1) NO313834B1 (de)
PL (1) PL203815B1 (de)
PT (2) PT1362597E (de)
TW (1) TWI261617B (de)
WO (1) WO2000002581A1 (de)

Families Citing this family (80)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN1254376A (zh) 1996-10-01 2000-05-24 杰龙公司 端粒酶逆转录酶
US7585622B1 (en) 1996-10-01 2009-09-08 Geron Corporation Increasing the proliferative capacity of cells using telomerase reverse transcriptase
US6475789B1 (en) 1996-10-01 2002-11-05 University Technology Corporation Human telomerase catalytic subunit: diagnostic and therapeutic methods
US7622549B2 (en) 1997-04-18 2009-11-24 Geron Corporation Human telomerase reverse transcriptase polypeptides
US7413864B2 (en) 1997-04-18 2008-08-19 Geron Corporation Treating cancer using a telomerase vaccine
WO1999050392A1 (en) 1998-03-31 1999-10-07 Geron Corporation Methods and compositions for eliciting an immune response to a telomerase antigen
US7402307B2 (en) 1998-03-31 2008-07-22 Geron Corporation Method for identifying and killing cancer cells
CA2344972A1 (en) * 1998-10-29 2000-05-11 Dana-Farber Cancer Institute, Inc. Cancer immunotherapy and diagnosis using universal tumor associated antigens, including htert
AU781376B2 (en) * 1999-04-09 2005-05-19 Biomira Inc. Telomerase-specific cancer vaccine
EP1257284A4 (de) * 2000-02-15 2005-12-21 Univ California Ein universelles vakzin und ein verfahren zur behandlung von krebs mit telomerase reverse transkriptase
WO2001060391A1 (en) 2000-02-15 2001-08-23 Regents Of The University Of California A universal vaccine and method for treating cancer employing telomerase reverse transcriptase
FR2812087B1 (fr) * 2000-07-21 2007-05-11 Inst Nat Sante Rech Med Procede de criblage de peptides utilisables en immunotherapie
GB0031430D0 (en) 2000-12-22 2001-02-07 Norsk Hydro As Polypeptides
GB0105238D0 (en) * 2001-03-02 2001-04-18 Norsk Hydro As Vaccines
GB0112342D0 (en) * 2001-05-21 2001-07-11 Norsk Hydro As Polypeptides
EP2463299A3 (de) * 2003-03-05 2012-10-17 Dendreon Corporation Zusammensetzungen und Verfahren unter Anwendung von Polypeptiden mit alternativem Leserahmen zur Behandlung von Krebs und Infektionskrankheiten
EP1748067A1 (de) * 2005-07-29 2007-01-31 Institut Pasteur Polynukleotide, die für MHC Klasse I-beschränkte Epitope der hTERT, Analoge und Polyepitope kodieren
US10767167B2 (en) 2005-07-29 2020-09-08 Institut Pasteur Polynucleotides encoding MHC class I-restricted hTERT epitopes, analogues thereof or polyepitopes
JP2009523817A (ja) * 2006-01-19 2009-06-25 ザ リージェンツ オブ ザ ユニバーシティ オブ カリフォルニア ヒトテロメラーゼ逆転写酵素ペプチド
US9732131B2 (en) 2006-02-27 2017-08-15 Calviri, Inc. Identification and use of novopeptides for the treatment of cancer
WO2008010010A1 (en) * 2006-07-12 2008-01-24 Vaxon Biotech Identification, optimization and use of cryptic hla-b7 epitopes for immunotherapy
EP1887084A1 (de) * 2006-08-10 2008-02-13 International Investment and Patents SA Plasmide mit immunologischer Wirkung
JP5207354B2 (ja) * 2008-03-12 2013-06-12 独立行政法人産業技術総合研究所 転写抑制ペプチド及びその遺伝子
DK2310044T3 (en) * 2008-06-16 2016-12-12 Mediolanum Farm S P A Antitumor IMMUNOTHERAPY
US20110318380A1 (en) * 2008-10-01 2011-12-29 Dako Denmark A/S MHC Multimers in Cancer Vaccines and Immune Monitoring
GB0821616D0 (en) 2008-11-26 2008-12-31 Lytix Biopharma As Compounds
MX346362B (es) 2009-11-10 2017-03-15 Allegro Pharmaceuticals Inc * Composiciones y metodos para inhibir la adhesion celular o dirigir agentes de diagnostico o terapeuticos a sitios de enlace rgd.
US11673914B2 (en) 2009-11-10 2023-06-13 Allegro Pharmaceuticals, LLC Peptide therapies for reduction of macular thickening
EP3581649A1 (de) 2010-02-16 2019-12-18 Ultimovacs ASA Polypeptide
FR2960542B1 (fr) * 2010-05-27 2012-08-17 Esther Suzy Arlette Fellous Peptide en tant que medicament, en particulier pour le traitement du cancer
WO2012154894A2 (en) 2011-05-09 2012-11-15 Allegro Pharmaceuticals, Inc. Integrin receptor antagonists and their methods of use
EP2875826B1 (de) * 2012-05-11 2017-08-23 KAEL-GemVax Co.,Ltd Zusammensetzung zur vorbeugung oder behandlung von sepsis
EP2847213B1 (de) * 2012-05-11 2018-01-03 KAEL-GemVax Co.,Ltd Entzündungshemmende peptide und zusammensetzung damit
KR102578891B1 (ko) 2012-05-11 2023-09-15 주식회사 젬백스앤카엘 항염증 활성을 갖는 펩티드 및 이를 포함하는 조성물
ES2981865T3 (es) * 2012-07-11 2024-10-10 Gemvax & Kael Co Ltd Conjugado que comprende un péptido de penetración celular y composiciones que comprenden el mismo
US20150125438A1 (en) 2012-07-20 2015-05-07 Sang Jae Kim Anti-Inflammatory Peptides and Composition Comprising the Same
KR102201429B1 (ko) 2012-09-19 2021-01-12 주식회사 젬백스앤카엘 세포 투과성 펩티드, 그를 포함한 컨쥬게이트 및 그를 포함한 조성물
TWI655204B (zh) 2012-09-19 2019-04-01 韓商傑姆維克斯＆凱爾有限公司 穿膜胜肽以及包含該胜肽之共軛物及組成物(三)
WO2014046481A1 (ko) * 2012-09-19 2014-03-27 주식회사 카엘젬백스 세포 투과성 펩티드, 그를 포함한 컨쥬게이트 및 그를 포함한 조성물
KR102038487B1 (ko) 2012-09-19 2019-10-30 주식회사 젬백스앤카엘 텔로머라제 펩티드를 포함하는 항균 또는 항진균용 조성물
TWI616530B (zh) * 2012-09-19 2018-03-01 傑姆維克斯＆凱爾有限公司 穿膜胜肽以及包含該胜肽之共軛物及組成物（一）
KR102166542B1 (ko) 2012-09-28 2020-10-16 주식회사 젬백스앤카엘 줄기세포 검출을 위한 텔로머라제 유래 펩티드 및 조영물질의 컨쥬게이트 및 이를 포함하는 조영제
CN102875657B (zh) * 2012-10-22 2014-04-09 南京工业大学 一种制备端粒酶多肽疫苗的方法
KR102106756B1 (ko) 2012-12-13 2020-05-06 주식회사 젬백스앤카엘 자외선에 의한 피부 손상 예방 또는 치료용 조성물
KR102093093B1 (ko) 2012-12-13 2020-03-25 주식회사 젬백스앤카엘 피부 노화 개선용 조성물
WO2014171792A1 (ko) * 2013-04-19 2014-10-23 주식회사 카엘젬백스 허혈성 손상 치료 및 예방용 조성물
WO2014178680A1 (ko) * 2013-05-03 2014-11-06 주식회사 카엘젬백스 Hsp 발현 억제 펩티드 및 이를 포함하는 조성물
CN105535931A (zh) 2013-06-07 2016-05-04 凯尔杰姆维克斯有限公司 在癌症免疫疗法中有用的生物标记
TWI539960B (zh) * 2013-06-21 2016-07-01 凱爾傑姆維克斯有限公司 激素分泌調節劑、包括其的組成物以及其用途
US9757473B2 (en) 2013-07-12 2017-09-12 Gemvax & Kael Co., Ltd. Cell-penetrating peptide and conjugate comprising same
KR102204476B1 (ko) * 2013-08-14 2021-01-19 주식회사 젬백스앤카엘 다발성 경화증 치료 및 예방용 조성물
GB201315946D0 (en) * 2013-09-06 2013-10-23 Immune Targeting Systems Its Ltd Oncology vaccine
CN105899224B (zh) * 2013-10-23 2019-12-13 珍白斯凯尔有限公司 用于治疗和预防良性前列腺增生的组合物
KR102494803B1 (ko) * 2013-11-22 2023-02-06 주식회사 젬백스앤카엘 혈관 신생 억제 활성을 가지는 펩티드 및 이를 포함하는 조성물
KR102106757B1 (ko) * 2013-11-29 2020-05-06 주식회사 젬백스앤카엘 난소 동결 보존용 펩티드 및 이를 포함하는 조성물
KR102667428B1 (ko) * 2013-12-10 2024-05-21 주식회사 젬백스앤카엘 항산화 효과를 가지는 펩티드 및 이를 포함하는 조성물
ES2809251T3 (es) * 2013-12-17 2021-03-03 Gemvax & Kael Co Ltd Composición para tratar cáncer de próstata
KR102166549B1 (ko) 2014-01-10 2020-10-16 주식회사 젬백스앤카엘 혈뇌장벽 투과성 펩티드 및 이를 포함하는 컨쥬게이트
KR101503341B1 (ko) * 2014-03-12 2015-03-18 국립암센터 자가암항원 특이적 cd8+ t 세포의 분리 및 증식방법
EP3130345B9 (de) 2014-04-11 2022-05-04 Gemvax & Kael Co., Ltd. Peptid mit fibrosehemmender wirkung und zusammensetzung damit
ES2962532T3 (es) 2014-04-30 2024-03-19 Gemvax & Kael Co Ltd Composición para el trasplante de órganos, tejidos o células, kit y procedimiento de trasplante
WO2015170790A1 (ko) * 2014-05-09 2015-11-12 주식회사 카엘젬백스 허혈성 손상 치료 및 예방용 조성물
CN105504016B (zh) * 2014-05-29 2019-01-01 生工生物工程（上海）股份有限公司 一种治疗癌症的肽变体及其应用
KR102166543B1 (ko) * 2014-06-02 2020-10-16 주식회사 젬백스앤카엘 켈로이드 억제용 조성물 및 그 억제 방법
KR102397510B1 (ko) * 2014-12-23 2022-05-13 주식회사 젬백스앤카엘 난소 기능 보존용 펩티드 및 이를 포함하는 조성물
KR102413243B1 (ko) 2014-12-23 2022-06-27 주식회사 젬백스앤카엘 안질환 치료 펩티드 및 이를 포함하는 안질환 치료용 조성물
EP3263122B1 (de) * 2015-02-27 2020-05-06 Gemvax & Kael Co., Ltd. Peptid zur verhinderung von hörverlust und zusammensetzung damit
KR20250073577A (ko) 2015-05-26 2025-05-27 주식회사 젬백스앤카엘 신규 펩티드 및 이를 포함한 조성물
WO2017003267A1 (ko) * 2015-07-02 2017-01-05 주식회사 젬백스앤카엘 항바이러스 활성 효능을 가지는 펩티드 및 이를 포함하는 조성물
KR20170054310A (ko) * 2015-11-09 2017-05-17 주식회사 젬백스앤카엘 텔로머라제 유래 펩티드를 포함하는 수지상세포 치료제 및 면역 치료제, 및 이를 사용하는 치료방법
WO2017176087A1 (ko) 2016-04-07 2017-10-12 주식회사 젬백스앤카엘 텔로머라제 활성 증가 및 텔로미어 연장 효능을 가지는 펩티드 및 이를 포함하는 조성물
JP6609724B1 (ja) 2017-01-06 2019-11-20 ユーティレックス カンパニー リミテッド 抗ヒト４−１ｂｂ抗体およびその使用
EP3576764A4 (de) 2017-02-03 2020-12-16 The Medical College of Wisconsin, Inc. Kras-peptid-impfstoffzusammensetzungen und verfahren zur verwendung
CN110996970A (zh) 2017-06-02 2020-04-10 亚利桑那州立大学董事会 创建个性化癌症疫苗的方法
US12025615B2 (en) 2017-09-15 2024-07-02 Arizona Board Of Regents On Behalf Of Arizona State University Methods of classifying response to immunotherapy for cancer
WO2020002650A1 (en) 2018-06-29 2020-01-02 Targovax Asa A formulation
EP4038222A4 (de) 2019-10-02 2023-10-18 Arizona Board of Regents on behalf of Arizona State University Verfahren und zusammensetzungen zur identifizierung von neoantigenen zur verwendung bei der behandlung und vorbeugung von krebs
US20230134801A1 (en) * 2020-04-17 2023-05-04 Lineage Cell Therapeutics, Inc. Mhc restricted immunogenic telomerase reverse transcriptase -specific peptides, their complex conjugates, and methods of using the same
AU2024285799A1 (en) * 2023-06-08 2025-12-18 Gemvax & Kael Co., Ltd. Composition comprising gv1001 for preventing or treating periodontal diseases and disorders caused by periodontal diseases
WO2025123051A1 (en) * 2023-12-07 2025-06-12 Endevica Bio, Inc. Non-naturally occurring melanocortin analogs and uses thereof for modulating weight gain

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB9103974D0 (en) 1991-02-26 1991-04-10 Norsk Hydro As Therapeutically useful peptides or peptide fragments
CA2192655A1 (en) 1994-06-14 1995-12-21 Edgar G. Engleman Methods for in vivo t cell activation by antigen-pulsed dendritic cells
US5968506A (en) 1995-08-04 1999-10-19 Geron Corporation Purified telomerase
CA2244110A1 (en) * 1996-02-12 1997-08-14 Cobra Therapeutics Limited Novel methods of vaccination and vaccines thereof comprising a nucleic acid encoding a first epitope and a peptide containing a second epitope
BR9708387A (pt) 1996-03-28 2000-01-04 Genitrix Llc Processo para vacinação de um mamìfero a um antìgeno selecionado, células patogênica e hospedeira, composição de vacina, ácido nucleico, e, opsonina engenheirada.
DE69733255T2 (de) * 1996-07-08 2006-01-19 Vivoxid Oy Bioabbaubares material mit hoher schlagzähigkeit
US5770422A (en) 1996-07-08 1998-06-23 The Regents Of The University Of California Human telomerase
CN1254376A (zh) * 1996-10-01 2000-05-24 杰龙公司 端粒酶逆转录酶
US7390891B1 (en) * 1996-11-15 2008-06-24 Amgen Inc. Polynucleotides encoding a telomerase component TP2
WO1999050392A1 (en) 1998-03-31 1999-10-07 Geron Corporation Methods and compositions for eliciting an immune response to a telomerase antigen
US6337200B1 (en) 1998-03-31 2002-01-08 Geron Corporation Human telomerase catalytic subunit variants

Also Published As

Publication number Publication date
HUP0104889A3 (en) 2004-04-28
EP2258383A3 (de) 2011-05-11
DK1362597T3 (da) 2010-06-14
US20060106196A1 (en) 2006-05-18
ATE247484T1 (de) 2003-09-15
HK1039068B (zh) 2009-02-06
EP1362597B2 (de) 2014-06-25
DK1093381T4 (da) 2009-09-21
CY1109978T1 (el) 2014-09-10
CZ200137A3 (en) 2001-06-13
EP1093381B2 (de) 2009-07-22
EP2258383A2 (de) 2010-12-08
HK1039068A1 (zh) 2002-04-12
EP2316476A2 (de) 2011-05-04
ES2200526T5 (es) 2009-12-11
AR077576A2 (es) 2011-09-07
AU756094B2 (en) 2003-01-02
PT1362597E (pt) 2010-04-14
CA2748996A1 (en) 2000-01-20
EP2316476B1 (de) 2015-11-25
AU4534099A (en) 2000-02-01
ES2200526T3 (es) 2004-03-01
CN1313773A (zh) 2001-09-19
DE69910580T2 (de) 2004-06-24
ES2341170T3 (es) 2010-06-16
PL345541A1 (en) 2001-12-17
NO983141L (no) 2000-01-10
US7030211B1 (en) 2006-04-18
PT1093381E (pt) 2004-01-30
AR020601A1 (es) 2002-05-22
TWI261617B (en) 2006-09-11
JP4618657B2 (ja) 2011-01-26
US7794723B2 (en) 2010-09-14
HU230007B1 (en) 2015-04-28
DK1093381T3 (da) 2003-09-08
PL203815B1 (pl) 2009-11-30
EP2316476A3 (de) 2011-09-14
DE69942072D1 (de) 2010-04-08
CA2336743A1 (en) 2000-01-20
EP1093381A1 (de) 2001-04-25
NO313834B1 (no) 2002-12-09
DE69910580T3 (de) 2009-11-26
WO2000002581A1 (en) 2000-01-20
JP5491315B2 (ja) 2014-05-14
CZ303215B6 (cs) 2012-05-30
EP1362597B1 (de) 2010-02-24
CN100376290C (zh) 2008-03-26
JP2010252810A (ja) 2010-11-11
EP1093381B1 (de) 2003-08-20
EP2258383B1 (de) 2016-03-09
HUP0104889A2 (hu) 2002-04-29
EP1362597A1 (de) 2003-11-19
JP2002520293A (ja) 2002-07-09
CA2336743C (en) 2011-10-11
DE69910580D1 (de) 2003-09-25
ES2341170T5 (es) 2014-09-09

Similar Documents

Publication Publication Date Title
ATE247484T1 (de) Von der telomerase abgeleitete antigene peptide
ATE317854T1 (de) Hepatitis c inhibitor peptide
NO982097D0 (no) Peptider
NO982098L (no) Peptider
NO2010013I1 (no) Rekombinant FSH-CTP
DK1042359T3 (da) k-Opioidreceptorpeptider
CY2007012I1 (el) Αντισωματα anti-vegf
DE69722620D1 (de) Nicht-waessrige protische peptidzubereitungen
ID24289A (id) Benzotiazol inhibitor-inhibitor protein terosin kinase
FI965032L (fi) Interleukiini-5-spesifisiä yhdistelmä-vasta-aineita
FI961350L (fi) Hapteenimerkityt peptidit
ID23159A (id) Wafer dan pembuatannya
NO985680D0 (no) Peptidderivater
ZA9811316B (en) Novel hepatitis C virus NS5B protein
EP1173467A4 (de) Von chemokinen abgeleitete synthetische peptide
NO983849L (no) Peptidderivater
DE69931010D1 (de) Peptide mit osteogener Aktivität
FI970168A7 (fi) Peptidejä
FI964363L (fi) Peptidejä
DE60042130D1 (de) Neue antigene hev-peptide und methoden
ID26730A (id) Induksi protein-protein dan peptida-peptida antibiotik oleh lait/scd14-protein
DE69427363D1 (de) Plättchenaggregationsinhibierende peptide
DK0950063T3 (da) Flergrenede peptidkonstruktioner
NO20005547D0 (no) Myelinbasiske proteinpeptider og anvendelser derav
NO20012283D0 (no) Koblede peptider

Legal Events

Date Code Title Description
UEP Publication of translation of european patent specification

Ref document number: 1362597

Country of ref document: EP